Esperion Therapeutics Inc. (ESPR) was one of the Russell 2000's biggest losers for Monday January 18 as the stock slid 10.58% to $13.77, a loss of $-1.63 per share. Starting at an opening price of $14.56 a share, the stock traded between $13.50 and $14.72 over the course of the trading day. Volume was 702,068 shares over 7,244 trades, against an average daily volume of 897,306 shares and a total float of 22.52 million.
The losses send Esperion Therapeutics Inc. down to a market cap of $310.09 million. In the last year, Esperion Therapeutics Inc. has traded between $120.96 and $13.11, and its 50-day SMA is currently $24.27 and 200-day SMA is $59.35.
Esperion Therapeutics Inc is engaged in the research, development and commercialization of therapies for the treatment of patients with elevated levels of elevated levels of LDL-C.
Esperion Therapeutics Inc. is based out of Ann Arbor, MI and has some 21 employees. Its CEO is Timothy M. Mayleben.
For a complete fundamental analysis analysis of Esperion Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for ESPR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer